XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. More Details
High growth potential with excellent balance sheet.
Share Price & News
How has XOMA's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XOMA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: XOMA underperformed the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: XOMA matched the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is XOMA's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StXOMA (NASDAQ:XOMA) Share Prices Have Dropped 15% In The Last Three Years
1 month ago | Simply Wall StIs XOMA (NASDAQ:XOMA) Using Too Much Debt?
2 months ago | Simply Wall StWhat Type Of Shareholders Make Up XOMA Corporation's (NASDAQ:XOMA) Share Registry?
Is XOMA undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XOMA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XOMA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XOMA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: XOMA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XOMA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XOMA is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.4x).
How is XOMA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XOMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: XOMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XOMA's is expected to become profitable in the next 3 years.
Revenue vs Market: XOMA's revenue (37.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: XOMA's revenue (37.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time
How has XOMA performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XOMA is currently unprofitable.
Growing Profit Margin: XOMA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XOMA is unprofitable, but has reduced losses over the past 5 years at a rate of 40.7% per year.
Accelerating Growth: Unable to compare XOMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XOMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: XOMA has a negative Return on Equity (-24.57%), as it is currently unprofitable.
How is XOMA's financial position?
Financial Position Analysis
Short Term Liabilities: XOMA's short term assets ($52.3M) exceed its short term liabilities ($11.3M).
Long Term Liabilities: XOMA's short term assets ($52.3M) exceed its long term liabilities ($38.2M).
Debt to Equity History and Analysis
Debt Level: XOMA's debt to equity ratio (81%) is considered high.
Reducing Debt: XOMA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XOMA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XOMA has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.4% each year
What is XOMA current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XOMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XOMA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XOMA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Neal (64 yo)
Mr. James R. Neal, also known as Jim, serves as Director at Leading BioSciences Inc since October 30, 2018. He has been the Chief Executive Officer at XOMA Corporation since December 21, 2016 and served as ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD1.48M) is about average for companies of similar size in the US market ($USD1.23M).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
|CEO & Director||3.83yrs||US$1.48m||0.19% |
|Senior VP of Finance & CFO||5.5yrs||US$813.21k||0.059% |
|VP & General Counsel||2.75yrs||no data||no data|
Experienced Management: XOMA's management team is considered experienced (3.8 years average tenure).
|CEO & Director||3.83yrs||US$1.48m||0.19% |
|Independent Director||10.17yrs||US$166.99k||0.059% |
|Independent Director||7.83yrs||US$159.99k||0.056% |
|Chairman of the Board & Lead Independent Director||9.17yrs||US$200.99k||0.090% |
|Independent Director||3.67yrs||US$145.99k||0.11% |
|Independent Director||1.75yrs||US$350.39k||0% |
|Director||0.25yr||no data||no data|
Experienced Board: XOMA's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.2%.
XOMA Corporation's company bio, employee growth, exchange listings and data sources
- Name: XOMA Corporation
- Ticker: XOMA
- Exchange: NasdaqGM
- Founded: 1981
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$258.706m
- Shares outstanding: 11.02m
- Website: https://www.xoma.com
Number of Employees
- XOMA Corporation
- 2200 Powell Street
- Suite 310
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XOMA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 1986|
|X0M1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 1986|
|0M26||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 1986|
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and tec ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/27 00:22|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.